Perimeter Medical Imaging AI (TSXV: PINK) On The Road to Commercialization With Strong Cash Position and A-List Leadership

Ticker Symbol: PINK (TSX Venture Exchange)
Shares Outstanding: 38.86 million
Market capitalization (10-19-2020): $75 million (CAD)
Global Addressable Market Size (Consumables): $3.7 billion 
(WHO Projections for 2020)

Backed by a multi-million dollar grant from the prestigious Cancer Prevention and Research Institute of Texas (CPRIT), Perimeter Medical Imaging AI (TSX Venture: PINK) is revolutionizing cancer surgery by developing an artificial intelligence (AI) and machine learning “plug in” to augment their proprietary, innovative ultrahigh resolution medical imaging system (which has 100x higher resolution than MRI). 

Perimeter is currently focused on reducing the debilitating re-surgery rate (approximately 1 in 4 surgeries) resulting from cancer cells left behind during initial tissue-preserving breast cancer surgery. 

Unlike most emerging medical device companies, Perimeter is addressing an unmet medical need (i.e., NOT competing with technology already in the market from giants such as Medtronic, Stryker and Intuitive Surgical) with a technology that provides 8x to 100x improvement over existing imaging technologies.

The Company’s initial total addressable market size for the consumable alone, just in the breast cancer surgery market, is US$794 million per year. The total cumulative capital sales which would be associated with achieving that level of annual consumables revenue is over US$750M. Because this is a platform technology that can potentially be applied to other forms of cancer, as well as other parts of the cancer surgery workflow, a total global addressable market of $3.7 billion exists in just the consumable’s portion of their business model.

Perimeter also now owns the net current assets that were in the shell at the time of the RTO. As of September 30, if nothing had changed other than the market price of the publicly traded stock that the shell owned, the value of the net current assets that came to Perimeter from the shell would be close to $7 million, which is close to a year’s worth of gross cash burn at the time of the RTO.

Led by an accomplished, high profile, world class management team and advisory board, Perimeter continues to attract top-tier talent to its board of directors and is entering the 3rd quarter with a strong cash position.

Read our coverage on Perimeter’s most recent additions to the Board, including Aaron Davidson (Senior VP Corporate Development and CFO, Profound Medical, PROF on NASDAQ) and Steve Sapot (former Senior VP of medical sales of Faxitron) to the newly created position of Chief Commercial Officer.

Jeremy Sobotta (President and CFO), having been part of deploying over $4B in capital into M&A from the acquirer side while at Stryker, says “We believe Perimeter is well capitalized in order to support our clinical development and commercialization plans.”

The Company’s initiatives and accomplishments thus far are not going unnoticed.

DC Finance, with an active network of approx. 3,000 Ultra-High Net Worth family offices around the world, on October 15th hosted Perimeter Medical with Mr. Jeremy Sobotta, CEO of Perimeter, Dr. Ted James, Chief of Breast Cancer Surgery at Harvard Medical School, and Dr. Frank Prendergast (Perimeter Director), former Chairman Emeritus of The Mayo Clinic’s Cancer Center and Eli Lilly Board member for over 20 years.

The group delivered an impactful Q&A entitled “Physician Perspectives: Improving Breast Cancer Outcomes with Perimeter’s Disruptive Medical Technology and AI”. In his closing remarks Dr. Ted James described Perimeter’s OTIS platform as “the Holy Grail of breast cancer surgery.” The full presentation can be found here.

Perimeter was also recently featured on the Fox26 Houston Morning Show where Dr. Alastair Thompson, Section Chief of Breast Surgery at the Dan Duncan Comprehensive Cancer Center, explains how the Company’s A.I. and machine learning “plug in”, currently under development, is being used to detect cancer cells that may have otherwise been left behind during initial surgery.

The following is an excerpt from their recently release Second Quarter financials, providing an excellent overview of the Company’s accomplishments to date. The full press release can be found here.

Jeremy Sobotta, Perimeter’s President and Chief Financial Officer, stated, “We have achieved a number of key milestones in the last few months, including successfully transitioning to a public company and raising approximately $9.4 million in net proceeds from a private placement offering. With the potential for further capital proceeds of approximately $13.5 million from the exercise of associated warrants, along with approximately $8 million of available funding from the grant received from the Cancer Prevention and Research Institute of Texas, we believe Perimeter is well capitalized in order to support our clinical development and commercialization plans.”

Corporate Highlights

On September 1, 2020, Perimeter announced that Steve Sapot was appointed as its Chief Commercial Officer. Previously, Mr. Sapot was Senior Vice President of Medical Sales at Faxitron, a Hologic Company. His wealth of experience includes leading and scaling sales teams and commercializing capital equipment in breast cancer surgery.

In July 2020, Perimeter announced the initiation of its ATLAS AI Project, which will collect images of breast tumors to both train and test its ImgAssist AI technology that is currently under development. Perimeter will install its OTIS™ high-resolution imaging devices at partner sites, and enrollment is already underway at Baylor College of Medicine and M.D. Anderson Cancer Center. The ATLAS AI Project is backed by a US$7.4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Perimeter announced two new appointments to its Board of Directors. Mr. Ian Mortimer, President and Chief Financial Officer at Xenon Pharmaceuticals Inc. (XENE) and Mr. Aaron Davidson, CFO and Senior Vice President of Corporate Development at Profound Medical Inc. (PROF)(PRN) joined the Perimeter Board in July and August, respectively.


While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter/report/commentary piece/article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Furthermore, it is certainly possible for errors or omissions to take place regarding the profiled company, in communications, writing and/or editing.

Nothing in this publication should be considered as personalized financial advice. We are not licensed under any securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. The information provided in this article is for informational purposes only and is not a recommendation to buy or sell any security. Please consult a licensed financial advisor before making any investment decision. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a website owned by Mountain Capital Corp (“Mountain”), (100 King Street West #5700, Toronto, Ontario). Mountain has been retained by Perimeter Medical Imaging AI Inc (“Perimeter”). to provide strategic digital media, marketing and data analytics services on behalf of the company for an undefined term. The agreement with Perimeter provides for a one-time cash-only payment. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision.

By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing Mountain Capital Corp, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

Please refer to our complete Disclaimer and Disclosure here